Human Microbiome Market worth $1.7 billion by 2029

"The Asian market has garnered significant attention from global players due to the increased focus on preventative healthcare and personalized medicine, driving the demand for human microbiomes."

Human Microbiome Market in terms of revenue was estimated to be worth $0.3 billion in 2023 and is poised to reach $1.7 billion by 2029, growing at a CAGR of 36.1% from 2023 to 2029 according to a new report by MarketsandMarkets™. Some of the prominent factors driving the growth of this market are advancements in technology, and the increasing awareness of personalized medicine are boosting the growth of the market. However, the regulatory challenges and limited understanding of microbial interactions can hamper the market growth.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

The human microbiome industry is poised for exponential growth and transformative advancements in the near future. As our understanding of the intricate relationship between the trillions of microbes living in and on our bodies expands, so does the potential for harnessing the power of the microbiome to revolutionize healthcare. With cutting-edge research, technological innovations, and collaborative efforts across various disciplines, the industry is set to unlock novel therapeutic approaches, diagnostic tools, and personalized treatments.

Therapeutic segment accounted for the largest share of the human microbiome market

Among the application, the human microbiome market is segmented into therapeutic, and diagnostics. In 2023, the therapeutic segment accounted for the largest share of the human microbiome market. Growth in this market segment can be attributed to increasing understanding of the crucial role that the microbiome plays in maintaining human health. It is also driven by increasing investment from pharmaceutical and biotechnology companies and the growing demand for personalized medicine.

Diagnostics segment is the fastest-growing segment of the human microbiome market

In 2023, the diagnostics segment accounted for the fastest-growing share of the application segment of human microbiome market. Market growth can largely be attributed to the advances in life science research on a vast number of diseases, and technological innovations in human genome mapping. The market is also driven by increasing investment from both the public and private sectors, rising prevalence of chronic diseases, regulatory support and guidelines, as well as the growing demand for personalized medicine.

Asia Pacific: The fastest-growing region in the human microbiome market.

The Asia Pacific human microbiome market is projected to grow at the highest CAGR during the forecast period, mainly due to increasing awareness of the importance of the microbiome in health and disease, the rising demand for personalized medicine, and advancements in sequencing technologies. The Asian market has also garnered significant attention from global players due to the increased focus on preventative healthcare and personalized medicine, driving the demand for human microbiomes.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

Key Market Players:

The market for human microbiome is highly consolidated, with key players strategizing to capture the market. Prominent players in the human microbiome market are Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), OptiBiotix Health Plc (UK), Ferring Pharmaceuticals (Switzerland), Synlogic, Inc. (US), Second Genome, Inc. (US), Vedanta Biosciences, Inc.  (US),  YSOPIA Bioscience (France), FlightPath Biosciences, Inc. (US), Finch Therapeutics Group, Inc. (US), AOBiome Therapeutics (US), BioGaia (Sweden), Quantbiome, Inc. (dba Ombre) (US), Viome Life Sciences, Inc. (US), BIOHM Health (US), DayTwo (US), Atlas Biomed (UK), Bione Ventures Private Limited (India), Luxia Scientific (France), Metabiomics (US), Sun Genomics (US), Seed Health (US), and Gnubiotics Sciences (Switzerland).

Recent Developments:

• In November 2021, Seres Therapeutics collaborated with Bacthera to manufacture SER-109. The company is a leading manufacturer for recurrent Clostridioides difficile infection (rCDI). As per the agreement, Bacthera is establishing a dedicated facility for commercial manufacturing in its new Microbiome Center of Excellence, a manufacturing site dedicated to the production of LBPs located on Lonza's Ibex campus in Visp, Switzerland.
• In June 2020, Enterome announced a new financing totaling $52.6million to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel 'OncoMimic' cancer immunotherapy.
• In July 2020, OptiBiotix Health PLC launched WellBiome, a revolutionary ingredient to support digestive, cardiovascular, and metabolic health.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=37621904

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/human-microbiome-market-37621904.html

Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Human Microbiome Market worth $1.7 billion by 2029